Cognitive impairment in long-COVID

被引:2
作者
Tozkir, Julide [1 ,3 ]
Turkmen, Cigdem [2 ]
Topcular, Baris [2 ]
机构
[1] Trakya Univ, Hlth Serv Vocat Coll, Balkan Yerleskesi, TR-22030 Edirne, Turkiye
[2] Abbott Prod Operat AG EPD, Basel, Switzerland
[3] Istanbul Florence Nightingale Hosp, Neurol Sci Ctr, Istanbul, Turkiye
来源
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE | 2024年 / 77卷 / 5-6期
关键词
COVID-19; long-COVID; cognition; cognitive impairment; brain fog; TOOL;
D O I
10.18071/isz.77.0151
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background - Long Covid is a complex condition characterised by symptoms that persist for weeks and months after the Co vid infection, accompanied by cognitive impairment that negatively affects daily life. Understanding this complex condition is important for the development of diagnostic and therapeutic strategies. Purpose - This article aims to provide a comprehensive overview of cognitive impairment in long-COVID, including its definition, symptoms, pathophysiology, risk factors, assessment tools, imaging abnormalities, potential biomarkers, management strategies, long-term outcomes, and future directions for research. Methods - The search methodology used in this review aimed to include a wide range of research on cognitive impairment related to both COVID-19 and long-COVID. Systematic searches of PubMed and Google Scholar databases were conducted using a mixture of MeSH terms and keywords including 'cognition', 'cognitive impairment', 'brain fog', 'COVID-19' and 'long-COVID'. The search was restricted to studies published in English between 1 January 2019 and 11 February 2024, which presented findings on neurological manifestations in human participants. Results - Long-COVID is characterized by persistent symptoms following COVID-19 infection, with cognitive impairment being a prominent feature. Symptoms include brain fog, difficulties with concentration, memory issues, and executive function deficits. Pathophysiological mechanisms involve viral persistence, immune responses, and vascular damage. Risk factors include age, pre-existing conditions, and disease severity. Cognitive assessment tools such as the Montreal Cognitive Assessment (MoCA) are essential for diagnosis. Imaging studies, including MRI, PET, and SPECT, reveal structural and functional brain alterations. Potential biomarkers include C -reactive protein, interleukin-6, and neuron -specific enolase. Management strategies encompass cognitive rehabilitation, occupational therapy, medications, and lifestyle modifications. Discussion - Long-COVID poses a multifaceted challenge, and cognitive impairment significantly impacts patients' lives. A multi- disciplinary approach, including cognitive rehabilitation and medication when appro- priate, is essential for effective management. Future research should focus on validating biomarkers and understanding long-term cognitive outcomes. Conclusion - Long-COVID is a global health concern, and cognitive impairment is a distressing symptom. While pharmacological interventions have potential, they require careful consideration. Continued research is crucial for improving the understanding and treatment of cognitive impairment in long-COVID.
引用
收藏
页数:69
相关论文
共 51 条
  • [1] Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review
    Alnefeesi, Yazen
    Siegel, Ashley
    Lui, Leanna M. W.
    Teopiz, Kayla M.
    Ho, Roger C. M.
    Lee, Yena
    Nasri, Flora
    Gill, Hartej
    Lin, Kangguang
    Cao, Bing
    Rosenblat, Joshua D.
    McIntyre, Roger S.
    [J]. FRONTIERS IN PSYCHIATRY, 2021, 11
  • [2] [Anonymous], 2020, Overview textbar COVID-19 rapid guideline: managing the longterm effects of COVID-19 textbar Guidance textbar NICE
  • [3] Ashraf MA, 2023, StatPearls
  • [4] Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
    Blazhenets, Ganna
    Schroeter, Nils
    Bormann, Tobias
    Thurow, Johannes
    Wagner, Dirk
    Frings, Lars
    Weiller, Cornelius
    Meyer, Philipp T.
    Dressing, Andrea
    Hosp, Jonas A.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (07) : 910 - 915
  • [5] Bohn C, 2022, Proceedings of IMPRS, V5, DOI [10.18060/26857, DOI 10.18060/26857]
  • [6] Persistent Symptoms in Patients After Acute COVID-19
    Carfi, Angelo
    Bernabei, Roberto
    Landi, Francesco
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (06): : 603 - 605
  • [7] Predictors of Cognitive Dysfunction One-Year Post COVID-19
    Cavaco, Sara
    Sousa, Gabriela
    Goncalves, Ana
    Dias, Alexandre
    Andrade, Carlos
    Pereira, Diogo
    Aires, Elaine Araujo
    Moura, Joao
    Silva, Lenia
    Varela, Ricardo
    Malheiro, Sofia
    Oliveira, Vanessa
    Teixeira-Pinto, Armando
    Maia, Luis F.
    Correia, Manuel
    [J]. NEUROPSYCHOLOGY, 2023, 37 (05) : 557 - 567
  • [8] Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group
    Caze, Ana B.
    Cerqueira-Silva, Thiago
    Bomfim, Adriele P.
    de Souza, Gisley L.
    Azevedo, Amanda C. A.
    Brasil, Michelle Q. A.
    Santos, Nara R.
    Khouri, Ricardo
    Dan, Jennifer
    Bandeira, Antonio C.
    Cavalcanti, Luciano P. G.
    Barral-Netto, Manoel
    Barral, Aldina
    Barbosa, Cynara G.
    Boaventura, Viviane S.
    [J]. JOURNAL OF GLOBAL HEALTH, 2023, 13
  • [9] CDC, 2023, Post-COVID conditions: information for healthcare providers
  • [10] MR Diffusion Tensor Imaging: A Window into White Matter Integrity of the Working Brain
    Chanraud, Sandra
    Zahr, Natalie
    Sullivan, Edith V.
    Pfefferbaum, Adolf
    [J]. NEUROPSYCHOLOGY REVIEW, 2010, 20 (02) : 209 - 225